Kipp
Palmer Memorial Golf Tournament (PA)
June 24, 2005
On July 4, 1999 our
good friend Kipp Palmer passed away from complications due to
Primary Pulmonary Hypertension. Not only was Kipp a great golfer,
but he was a fighter who, in the end, couldn't prevail over PPH.
Help us remember Kipp on June 24th while contributing to the good
cause of PPH cure research.
The California
PH Forum offers support and medical updates for patients, their
families, friends, and medical professionals interested in Pulmonary
Arterial Hypertension. It is presented in the years in between
the Pulmonary Hypertension Association's biennial international
conferences.
Encysive Pharmaceuticals Announces
New STRIDE-2 Data Presented at American Thoracic Society International
Conference
HOUSTON, May 23, 2005 /PRNewswire-FirstCall/
-- Encysive Pharmaceuticals today presented additional data from
STRIDE-2, the Company's second randomized, pivotal Phase III clinical
trial of Thelin(TM) (sitaxsentan) for the treatment of pulmonary
arterial hypertension (PAH) at the annual International Conference
of the American Thoracic Society (ATS) in San Diego. The data was
presented in an oral session by Robyn J. Barst, M.D., Professor
of Pediatrics at Columbia University College of Physicians and Surgeons,
and Director, New York Presbyterian Hospital Pulmonary Hypertension
Center.
Researchers Present Data That Support
Inhaled Iloprost Therapy in Patients With Pulmonary Arterial Hypertension
SAN DIEGO, Calif., May 23, 2005 /PRNewswire-FirstCall/
-- CoTherix, Inc. announced today that researchers have presented results
involving inhaled iloprost therapy for the treatment of pulmonary arterial
hypertension (PAH), a debilitating and potentially fatal disease characterized
by high blood pressure in the pulmonary arteries. Results were presented
at the American Thoracic Society (ATS) International Conference in San
Diego during the Thematic Poster Session for Pulmonary Hypertension.
FDA
approval puts F.C. firm on firm ground to pursue drug
FORT COLLINS - A Fort Collins
biotechnology company, best known for its work on veterinary pharmaceuticals,
has made the leap into human medicine.
PR Pharmaceuticals recently obtained orphan
drug status from the U.S. Food and Drug Administration for PulmoLAR, a
drug the company is developing for treatment of pulmonary arterial hypertension.
Pulmonary
Hypertension - A Patient's Survival Guide The premiere information resource
for people dealing with PH -- they have ARRIVED and are ready to
ship!!!
The author, a PH patient herself,
knows what it is like to live with the disease. She talked to many
other patients, doctors, and researchers while writing the Survival
Guide. Dr. Ronald J. Oudiz and a team of physicians with a deep
knowledge of PH edited the book for accuracy.
New edition contains a chart
of 15 drugs used to treat PH; results of recent
clinical trials;
in-depth discussion of PH secondary to other diseases
or conditions;
a new chapter on what to eat if you have PH; and much, much more!
Ambrisentan PAH Long-Term Safety and Efficacy Data Presented
at ATS 2005 San Diego
DENVER, May 23 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG),
a biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disorders, today announced that two abstracts describing
the effects of ambrisentan in patients with pulmonary arterial hypertension
(PAH) were presented at ATS 2005 - San Diego, the annual International
Conference of the American Thoracic Society.
CT Scan Findings in Chronic
Thromboembolic Pulmonary Hypertension*: Predictors of Hemodynamic Improvement
After Pulmonary Thromboendarterectomy
Study objectives: The aim
was to correlate CT scan findings with hemodynamic measurements in patients
who had undergone pulmonary thromboendarterectomy (PTE) and to evaluate
whether CT scan findings can help to predict surgical outcome.
The
information provided on the PHA website is provided for general information
only. It is not intended as legal, medical or other professional
advice, and should not be relied upon as a substitute for consultations
with qualified professionals who are familiar with your individual
needs.
